Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Aligos Therapeutics (ALGS) Asset Writedowns and Impairment (2023)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Historic Asset Writedowns and Impairment for Aligos Therapeutics (ALGS) over the last 1 years, with Q2 2023 value amounting to $700000.0.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|